Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reissue Patent
2005-06-14
2005-06-14
Tsang, Cecilia J. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S054000, C536S021000, C536S055300, C536S124000
Reissue Patent
active
RE038743
ABSTRACT:
Heterogeneous intimate admixtures of sulfated heparinic polysaccharides, well suited for the prophylaxis/treatment of acute thrombotic episodes in a human patient, comprise immixture of sulfated polysaccharides having a weight average molecular weight less than that of heparin and which include from 9% to 20% of polysaccharide chains having a molecular weight less than 2,000 daltons and from 5% to 20% of polysaccharide chains having a molecular weight greater than 8,000 daltons, the ratio between the weight average molecular weight and the number average molecular weight thereof ranging from 1.3 to 1.6.
REFERENCES:
patent: 3766167 (1973-10-01), Lasker et al.
patent: 3891622 (1975-06-01), Mardiguian et al.
patent: 4303651 (1981-12-01), Lindahl et al.
patent: 4351938 (1982-09-01), Barnett
patent: 4401662 (1983-08-01), Lormeau et al.
patent: 4440926 (1984-04-01), Mardiguian
patent: 4486420 (1984-12-01), Lormeau et al.
patent: 4652555 (1987-03-01), Goulay et al.
patent: 4692435 (1987-09-01), Lormeau et al.
patent: 4981955 (1991-01-01), Lopez
patent: 4987222 (1991-01-01), De Ambrosi et al.
patent: 4990502 (1991-02-01), Lormeau et al.
patent: 5019649 (1991-05-01), Lormeau et al.
patent: 5106734 (1992-04-01), Nielsen
patent: 70519/81 (1981-11-01), None
patent: 160764 (1987-04-01), None
patent: 0040144 (1981-11-01), None
patent: 0 066 908 (1982-12-01), None
patent: 0 040 144 (1984-08-01), None
patent: 0 133 078 (1985-02-01), None
patent: 0 293 539 (1987-01-01), None
patent: 0 244 235 (1987-11-01), None
patent: 0 244 236 (1987-11-01), None
patent: 0 301 618 (1989-02-01), None
patent: 0 337 327 (1989-10-01), None
patent: 0 380 719 (1990-08-01), None
patent: A-8206555 (1982-11-01), None
patent: 2 003 197 (1988-10-01), None
patent: A-2006891 (1989-05-01), None
patent: 2 739 (1964-08-01), None
patent: 2 548 672 (1985-01-01), None
patent: 2 663 639 (1991-12-01), None
patent: 1 501 095 (1978-02-01), None
patent: 188 667 (1989-04-01), None
patent: 51283 (1986-11-01), None
patent: 1248557 (1995-01-01), None
patent: 36492/85 (1985-02-01), None
patent: 283103/87 (1987-11-01), None
patent: WO 81/03276 (1981-11-01), None
English language translation of EP 0 040 144 B1.
English language translation of EP 0 293 539 A2.
English language abstract of ES 2 003 197.
Paragraph IV certification letter of Jun. 24, 2003, from Teva Pharmaceuticals, USA.
Béguin, S. et al., The Mode of Action of Low Molecular Weight Heparin Preparation (PK10169) and Two of its Major Components on Thrombin Generation in Plasma,Thrombos. Haemostas.61(1): 30-34 (1989).
Dahan, R. et al., “Prevention of Deep Vein Thrombosis in Elderly Medical In-Patients by Low Molecular Weight Heparin (Enoxaparin): Randomized Double Blind Trial,” Abstract SS36 from the XthInternational Congress on Thrombosis and Haemostasis,Thrombos. Haemostas.54(1):309 (1985).
Fareed, J. et al., “Biochemical and Pharmacologic Inequivalence of Low Molecular Weight Heparins,”Ann. N.Y. Acad. Sci.556:333-353 (1989).
Fareed, J. et al., “Chemical and Biological Heterogeneity in Low Molecular Weight Heparins: Implications for Clinical Use and Standardization,”Seminars in Thrombosis and Hemostasis,15(4):440-463 (1989).
Fareed, J. et al., “Comparative Study on the in vitro and in vivo Activities of Seven Low-Molecular-Weight Heparins,”Haemostasis18 (Suppl. 3), pp. 3-15 (1988).
Forbes, C.D., “Prevention of Deep Vein Thrombosis—Use of the Low Molecular Weight Heparin Enoxaparin,”British J. Clin. Prac.43(11): 396-400 (1989).
Frydman, A.M. et al., “The Antithrombolic Activity and Pharmacokinetics of Enoxaparine, a Low Molecular Weight Heparin, in Humans Given Single Subcutaneous Doses of 20 to 80 mg,”J. Clin. Pharmacol.28:609-618 (1988).
Linhardt, R.J. et al., “Oligosaccharide Mapping of Low Molecular Weight Heparins: Structure and Activity Differences,”J. Med. Chem.33:1639-1645 (1990).
Planes, A. et al., “Enoxaparin, Low Molecular Weight Heparin (LMWH): Its Use in Prevention of Deep Venous Thrombosis (DVT) Following Total Hip Replacement (THR),” Abstract SS35 from the XthInternational Congress on Thrombosis and Haemostasis,Thrombos, Haemostas.54(1):309 (1985).
Declaration Pursuant to 37 C.F.R. §1.132, by Dr. Uzan, in U.S. Appl. No. 08/072,577. Jun. 9, 1994.
Second Declaration Pursuant to 37 C.F.R. §1.132, by Dr. Uzan, In U.S. Appl. No. 08/072,577. Jun. 9, 1994.
Office Action of Apr. 2, 1992 in U.S. Appl. No. 08/072,577.
Office Action of Nov. 16, 1993 in U.S. Appl. No. 08/072,577.
Paragraph IV certification letter of Jun. 19, 2003, from Amphastar Pharmaceuticals, Inc.
Neville, G. A. et al., “Monitoring the Purity of Pharmaceutical Heparin Preparations by High-Field1H-Nuclear Magnetic Resonance Spectroscopy,”J. Pharm. Sci.78(2):101-104 (1989).
Turpie, A.G.G. et al., “A Randomized Controlled Trial of a Low-Molecular-Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip Surgery,”N. Engl. J. Med.315(15):925-929 (1986).
Huet, Y. et al., “Low Molecular Weight Heparin Fraction PK10169: A New Therapeutic Means for Anticoagulant Therapy?”Haemostasis16:165-172 (1986).
Dahan, R. et al., “Prevention of Deep Vein Thrombosis in Elderly Medical In-Patients by a Low Molecular Weight Heparin (Enoxaparin): A randomized Double-Blind Trial,”Haemostasis16: 159-164 (1986).
Planes, A. et al., “Enoxaparine Low Molecular Weight Heparin: Its Use in Prevention of Deep Venous Thrombosis Following Total Hip Replacement,”Haemostasis16: 152-158 (1986).
U.S. District Court Civil Docket (District of New Jersey; Aventis Pharma SA, et al. v. Amphastar Pharmaceut, et al.).
U.S. District Court Civil Docket (District of California; Aventis Pharma SA, et al. v. Amphastar Pharmaceut., et al.).
Aventis' Complaint, filed in District Court of New Jersey on Aug. 4, 2003.
Teva Pharmaceuticals USA's Answer and Counterclaims, filed Aug. 28, 2003, in the New Jersey court.
Aventis' Reply to Answer and Counterclaims of Teva, filed Aug. 29, 2003, in the New Jersey court.
Aventis' Complaint, filed in District Court of California on Aug. 4, 2003.
Amphastar Pharmaceuticals' Answer and Counterclaims, filed Aug. 25, 2003, in the California court.
Aventis' Reply to Answer and Counterclaims of Amphastar, filed Aug. 29, 2003, in the California court.
Teva's Answer and Counterclaims, filed Aug. 26, 2003, in the California court.
Aventis' Reply to Teva's Answer and Counterclaims, filed Aug. 29, 2003, in the California court.
English language translation of EP 0 133 078 A1.
(1) Verbale di Apetura delle Operazioni Peritali.
English language translation of (1). (Record of Initiation of Proceedings for Expert Opinion.).
(2) Prima memoria tecnica in favore delle attrici.
English language translation of (2). (First Technical Brief in Favor of Plaintiffs.).
(3) Seconda memoria tecnica in favore delle attrici.
English language translation of (3). (Second Technical Brief in Favor of Plaintiffs.).
(4) Terza memoria tecnica in favore della attrici.
English language translation of (4). (Third Technical Brief in Favor of Plaintiffs.).
(5) Quarta memoria tecnica in favore della attrici.
English language translation of (5). (Fourth Technical Brief in Favor of Plaintiffs.).
(6) Quinta memoria tecnica in favore della attrici.
English language translation of (6). (Fifth Technical Brief in Favor of Plaintiffs.).
(7) Prima memoria al C.T.U. nell'interresse della Aventis Pharma S.A.
English language translation of (7). (First Technical Brief in the Interest of Aventis Pharma S.A.).
(8) Seconda memoria tecnica al C.T.U. neli'interesse della Aventis Pharma S.A.
English language translation of (8). (Second Technical Brief in the Interest of Aventis Pharma S.A.).
(9) Terza memoria al C.T.U. nell'interesse di AVENTIS PHARMA S.A.
English language translation of (9). (Third Technical Brief in the Interest of Aventis Pharma S.A.).
(10) Quarta memoria tecnica a favore di AVENTIS S.A.
English language translation of (10). (F
Aventis Pharma S.A.
Finnegan Henderson Farabow Garrett & Dunner LLP
Maier Leigh C.
Tsang Cecilia J.
LandOfFree
Mixtures of particular LMW heparinic polysaccharides for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mixtures of particular LMW heparinic polysaccharides for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mixtures of particular LMW heparinic polysaccharides for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3479343